Quinazoline derivatives as anticancer drugs: a patent review (2011 – present)

Bibliography

• Griess P. Ueber die Einwirkung des Cyans auf Anthranilsäure. Berichte 1869;2:415-18
   Google Scholar
• Griess P. Ueber die Einwirkung von Cyan auf Amidobenzoësäure und Anthranilsäure in WässerigerLösung. Berichte 1878;11:1985-8
   Google Scholar
• Bischler A, Lang M. ZurKenntniss der Phenmiazinderivate. Chem Ber 1895;28:279-93
   Google Scholar
• Gabriel S, Colman J. ZurKenntniss des Pyrimidins und methylirter Pyrimidine. Chem Ber 1903;36:3379-85
   Google Scholar
• Wang D, Gao F. Quinazoline derivatives: synthesis and bioactivities. Chem Cent J 2013;7:95-110
   PubMed Web of Science ®Google Scholar
• Selvam TP, Kumar PV. Quinazoline marketed drugs - a review. Res Pharm 2011;1:1-21
   Google Scholar
• Vijayakumar B, Prasanthi P, Muni Teja K. Quinazoline derivatives & pharmacological activities: a review. IJMCA 2013;3:10-21
   Google Scholar
• Coatney GR, Cooper WC, Culwell WB. Studies in human malaria. XXV. Trial of febrifugine, an alkaloid obtained from Dichroafebrifugalour., against the Chesson strain of Plasmodium vivax. J Natl Malar Soc 1950;9:183-6
   Google Scholar
• Fishman M, Cruckshank PA. Febrifugine antimalarial agents. 1. Pyridine analogs of febrifugine. J Med Chem 1970;13:155-6
   PubMed Web of Science ®Google Scholar
• Zhu S, Chandrashekar G, Meng L, et al. Febrifugine analogue compounds: synthesis and antimalarial evaluation. Bioorg Med Chem 2012;20:927-32
   PubMed Web of Science ®Google Scholar
• Marzaro G, Guiotto A, Chilin A. Quinazoline derivatives as potential anticancer agents: a patent review (2007 - 2010). Expert Opin Ther Pat 2012;22:223-52
   PubMed Web of Science ®Google Scholar
• Bilbro J, Mart M, Kyprianou N. Therapeutic value of quinazoline-based compounds in prostate cancer. Anticancer Res 2013;33:4695-700
   Google Scholar
• Van Horn KS, Burda WN, Fleeman R, et al. Antibacterial Activity of a Series of N2,N4 Disubstituted Quinazoline-2,4-diamines. J Med Chem 2014;57:3075-93
   Google Scholar
• Lam T, Hilgers MT, Cunningham ML, et al. Structure-based design of new dihydrofolate reductase antibacterial agents: 7-(benzimidazol-1-yl)-2,4-diaminoquinazolines. J Med Chem 2014;57:651-68
   PubMed Web of Science ®Google Scholar
• Singh B, Sharma RA. Anti-inflammatory and antimicrobial properties of pyrroloquinazoline alkaloids from AdhatodavasicaNees. Phytomedicine 2013;20:441-5
   PubMed Web of Science ®Google Scholar
• Hu J, Zhang Y, Dong L, et al. Design, synthesis, and biological evaluation of novel quinazoline derivatives as anti-inflammatory agents against lipopolysaccharide-induced acute lung injury in rats. ChemBiol Drug Des 2014; Epub ahead of print
   Google Scholar
• Zhu S, Chandrashekar G, Meng L, et al. Febrifugine analogue compounds: synthesis and antimalarial evaluation. Bioorg Med Chem 2012;20:927-32
   PubMed Web of Science ®Google Scholar
• Honkanen E, Pippuri A, Kairisalo P, et al. Synthesis and antihypertensive activity of some new quinazoline derivatives. J Med Chem 1983;26:1433-8
   PubMed Web of Science ®Google Scholar
• Capra M, Nuciforo PG, Confalonieri S, et al. Frequent alterations in the expression of serine/threonine kinases in human cancers. Cancer Res 2006;66:8147-54
   PubMed Web of Science ®Google Scholar
• Holderfield M, Deuker MM, McCormick F. Targeting RAF kinases for cancer therapy: BRAF-mutated melanoma and beyond. Nat Rev Cancer 2014;14:455-67
   PubMed Web of Science ®Google Scholar
• Wilhelm S, Carter C, Lynch M. Discovery and development of sorafenib: a multikinase inhibitor for treating cancer. Nat Rev Drug Discov 2006;5:835-44
   PubMed Web of Science ®Google Scholar
• Daiichi Sankyo Co Ltd Japan. Preparation of quinazoline derivatives as BRAF kinase inhibitors. WO 068187; 2011
   Google Scholar
• Peop Rep China. Quinazoline- substituted diphenyl urea derivatives as Raf kinase inhibitors and their preparation, pharmaceutical compositions and use in the treatment of leukemia and cancer. CN102311395; 2012
   Google Scholar
• Davies H, Bignell GR, Cox C, et al. Mutations of the BRAF gene in human cancer. Nature 2002;417:949-54
   PubMed Web of Science ®Google Scholar
• El-Nassan HB. Recent progress in the identification of BRAF inhibitors as anti-cancer agents. Eur J Med Chem 2014;72:170-205
   PubMed Web of Science ®Google Scholar
• Array BioPharmaInc USA; Genentech Inc. Preparation of N- (3- sulfonylaminophenyl) quinazoline- 8- carboxamides as Raf inhibitors. WO 2011025938; 2011
   Google Scholar
• Hemmings BA, Restuccia DF. PI3K-PKB/Akt pathway. Cold Spring Harb Perspect Biol 2012;4:a011189
   PubMed Web of Science ®Google Scholar
• Fruman DA, Rommel C. PI3K and cancer: lessons, challenges and opportunities. Nat Rev Drug Discov 2014;13:140-56
   PubMed Web of Science ®Google Scholar
• Welker ME, Kulik G. Recent syntheses of PI3K/Akt/mTOR signaling pathway inhibitors. Bioorg Med Chem 2013;21:4063-91
   PubMed Web of Science ®Google Scholar
• Merck Patent GmbH. Quinazoline derivatives as PI3 kinase inhibitors and their preparation. WO055466; 2012
   Google Scholar
• Exelixis Inc. Preparation of quinazoline compounds as PI3K inhibitors. WO160177; 2014
   Google Scholar
• Novartis AG. Preparation of quinazoline derivatives as PI3K modulators. WO057711; 2013
   Google Scholar
• Goldenson B, Crispino JD. The aurora kinases in cell cycle and leukemia. Oncogene 2015;34:537-45
   PubMed Web of Science ®Google Scholar
• Mortlock AA, Foote KM, Heron NM, et al. Discovery, synthesis, and in vivo activity of a new class of pyrazoloquinazolines as selective inhibitors of aurora B kinase. J Med Chem 2007;50:2213-24
   PubMed Web of Science ®Google Scholar
• Shenzhen Salubris Pharmaceuticals Co. Fused quinazoline derivatives as protein tyrosine kinase inhibitor and aurora kinase inhibitor and their preparation. WO144059; 2011
   Google Scholar
• F Hoffmann-la Roche AG. Aminoquinazoline and pyridopyrimidine derivatives as MAP4K4 inhibitors and their preparation. WO178591; 2013
   Google Scholar
• Vlahovic G, Crawford J. Activation of tyrosine kinases in cancer. Oncologist 2003;8:531-8
   PubMed Web of Science ®Google Scholar
• Lemmon MA, Schlessinger J. Cell signaling by receptor tyrosine kinases. Cell 2010;141:1117-34
   PubMed Web of Science ®Google Scholar
• Arora A, Scholar EM. Role of tyrosine kinase inhibitors in cancer therapy. J Pharmacol Exp Ther 2005;315:971-9
   PubMed Web of Science ®Google Scholar
• Denny WA. The 4-anilinoquinazoline class of inhibitors of the erbB family of receptor tyrosine kinases. Farmaco 2001;56:51-6
   PubMedGoogle Scholar
• Ocaña A, Pandiella A. Targeting HER receptors in cancer. CurrPharm Des 2013;19:808-17
   Google Scholar
• Roskoski RJr. The ErbB/HER family of protein-tyrosine kinases and cancer. Pharmacol Res 2014;79:34-74
   PubMed Web of Science ®Google Scholar
• Tianjin Inst Pharm Research. 6-substituted quinazoline derivative, preparation method and application thereof. CN102079759; 2011
   Google Scholar
• Qilu Pharmaceutical Co Ltd. 4-(Substituted Anilino)Quinazoline Derivatives As Tyrosine Kinase Inhibitors. WO035540; 2011
   Google Scholar
• Qilu Pharmaceutical Co Ltd. Polymorphic substances of 4-(substituted anilino)quinazoline derivative xylene sulfonate, and preparation method and application thereof. WO131465; 2013
   Google Scholar
• Tetranov International Inc. Bis-Quinazoline derivatives as inhibitors for epidermal growth factor receptor (EGFR) Tyrosine Kinase. US8916572; 2013
   Google Scholar
• Carmi C, Lodola A, Rivara S. Epidermal growth factor receptor irreversible inhibitors: chemical exploration of the cysteine-trap portion. Mini Rev Med Chem 2011;11:1019-930
   PubMedGoogle Scholar
• Carmi C, Mor M, Petronini PG, et al. Clinical perspectives for irreversible tyrosine kinase inhibitors in cancer. Biochem Pharmacol 2012;84:1388-99
   PubMed Web of Science ®Google Scholar
• Ou SH. Second-generation irreversible epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs): a better mousetrap? A review of the clinical evidence. Crit Rev Oncol Hematol 2012;83:407-21
   PubMed Web of Science ®Google Scholar
• Shanghai Allist Pharmaceuticals Inc. Quinazoline derivatives, preparation methods and uses thereof. WO09505; 2011
   Google Scholar
• Suzhou Metabomics Inc. Quinolinylcrotyl compound and its application in preparation of anti-malignant tumor drugs. CN102838550; 2012
   Google Scholar
• Kbp Biosciences Co Ltd. Quinazoline derivative as tyrosine-kinase inhibitor, preparation method therefor and application thereof. WO159457; 2012
   Google Scholar
• Shanghai Hengrui Pharm Co Ltd. 4-Quinazoline amine derivative and application thereof. WO2013131424; 2014
   Google Scholar
• Qilu Pharmaceutical Co Ltd. 4-(Substituted phenylamino)quinazoline compounds, and preparation method and application thereof. CN103965175; 2014
   Google Scholar
• KPB biosciences co Ltd. Quinazoline derivatives substituted by aniline, preparation method and use thereof. WO027960; 2012
   Google Scholar
• Shanghai Pharmaceuticals Holding Co Ltd. Quinazoline derivative, preparation method therefor, intermediate, composition and application thereof. WO013640; 2013
   Google Scholar
• Jiangsu Kanion Pharmaceutical. 4-Phenylamino-6-butenamide-7-alkyloxy quinazoline derivatives, preparative method and use thereof. WO155339; 2012
   Google Scholar
• Neuwgen Therapeutics Inc. Alkyne substituted quinazoline compound and methods of use. WO122058; 2012
   Google Scholar
• Shibuya M. Vascular endothelial growth factor (VEGF) and its receptor (VEGFR) signaling in angiogenesis: a crucial target for anti- and pro-angiogenic therapies. Genes Cancer 2011;2:1097-105
   PubMedGoogle Scholar
• Tie J, Desai J. Antiangiogenic therapies targeting the vascular endothelia growth factor signaling system. Crit Rev Oncog 2012;17:51-67
   PubMedGoogle Scholar
• Tugues S, Koch S, Gualandi L, et al. Vascular endothelial growth factors and receptors: Anti-angiogenic therapy in the treatment of cancer. Mol Aspects Med 2011;32:88-111
   PubMed Web of Science ®Google Scholar
• Rogosin S, Sandler AB. Beyond bevacizumab: antiangiogenic agents. Clin Lung Cancer 2012;13:326-33
   Google Scholar
• Univ Yunnan. Quinazolinearylurea and preparation method and application thereof. CN103102315; 2013
   Google Scholar
• Univ Zhejiang. 2-Fluoro-aniline quinazoline tumour positron imaging agents as well as preparation method and application thereof. CN103304493; 2013
   Google Scholar
• Univ Beijing Normal. Novel <18>F marked substituted quinazoline compound, and preparation method and tumor PET development application thereof. CN103254140; 2013
   Google Scholar
• BoehringerIngelheim Int. Radiolabeled quinazoline derivatives. WO118197; 2014
   Google Scholar
• Li S, Wang X, He Y, et al. Design and synthesis of novel quinazoline nitrogen mustard derivatives as potential therapeutic agents for cancer. Eur J Med Chem 2013;67:293-301
   PubMed Web of Science ®Google Scholar
• Marvania B, Lee PC, Chaniyara R, et al. Design, synthesis and antitumor evaluation of phenyl N-mustard-quinazoline conjugates. Bioorg Med Chem 2011;19:1987-98
   PubMed Web of Science ®Google Scholar
• Univ Beijing Normal. Two nitrogen mustard derivatives, as well as preparation method and application therefore in tumor treatment. CN103450096; 2013
   Google Scholar
• Univ Beijing Normal. Crown ether ring-shaped quinazoline nitrogen mustard compound, and preparation method and application thereof in tumor treatment. CN103601730; 2014
   Google Scholar
• Barneda-Zahonero B, Parra M. Histone deacetylases and cancer. Mol Oncol 2012;6:579-89
   PubMed Web of Science ®Google Scholar
• West AC, Johnstone RW. New and emerging HDAC inhibitors for cancer treatment. J Clin Invest 2014;124:30-9
   PubMed Web of Science ®Google Scholar
• Jiangsu Hengyi Pharmaceutical Co Ltd. 4-Aminoquinazoline derivatives and uses thereof. WO2012155806; 2014
   Google Scholar
• Millennium Pharm Inc. Substituted hydroxamic acids and uses thereof. US0094997; 2012
   Google Scholar
• Meitzler JL, Antony S, Wu Y, et al. NADPH oxidases: a perspective on reactive oxygen species production in tumor biology. Antioxid Redox Signal 2014;20:2873-89
   PubMed Web of Science ®Google Scholar
• Univ Emory. Quinazoline derivatives, compositions, and uses related thereto. WO181135; 2013
   Google Scholar
• Wang X, Chen M, Zhou J, et al. HSP27, 70 and 90, anti-apoptotic proteins, in clinical cancer therapy (Review). Int J Oncol 2014;45:18-30
   PubMed Web of Science ®Google Scholar
• Merck Patent Gmbh. Quinazoline derivatives. US238582; 2012
   Google Scholar
• Taiho Pharmaceutical Co. Ltd. Novel bicyclic compound or salt thereof. WO093708; 2012
   Google Scholar